Eph receptors as oncotargets.
作者信息
Charmsaz Sara, Boyd Andrew W
机构信息
Sara Charmsaz: Leukaemia Foundation of Queensland Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Department of Medicine, University of Queensland, Brisbane, QLD, Australia; Department of Surgery, Royal College of Surgeons, Dublin, Ireland.
出版信息
Oncotarget. 2017 Sep 19;8(47):81727-81728. doi: 10.18632/oncotarget.21045. eCollection 2017 Oct 10.
Abstract
摘要
相似文献
1
Eph receptors as oncotargets.作为癌靶标的Eph受体
Oncotarget. 2017 Sep 19;8(47):81727-81728. doi: 10.18632/oncotarget.21045. eCollection 2017 Oct 10.
2
Expression of Eph receptors and their ligands, ephrins, during lipopolysaccharide fever in rats.大鼠脂多糖发热期间Eph受体及其配体ephrins的表达
Physiol Genomics. 2005 Apr 14;21(2):152-60. doi: 10.1152/physiolgenomics.00043.2004. Epub 2005 Jan 25.
3
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.可溶性Eph A受体在体内可抑制肿瘤血管生成和进展。
Oncogene. 2002 Oct 10;21(46):7011-26. doi: 10.1038/sj.onc.1205679.
4
Expression and tyrosine phosphorylation of Eph receptors suggest multiple mechanisms in patterning of the visual system.Eph受体的表达及酪氨酸磷酸化表明视觉系统模式形成中存在多种机制。
Dev Biol. 1998 Jan 1;193(1):21-35. doi: 10.1006/dbio.1997.8786.
5
A paradigm shift in EPH receptor interaction: biological relevance of EPHB6 interaction with EPHA2 and EPHB2 in breast carcinoma cell lines.EPH 受体相互作用的范式转变：EPHB6 与 EPHA2 和 EPHB2 在乳腺癌细胞系中的相互作用的生物学意义。
Cancer Genomics Proteomics. 2011 Jul-Aug;8(4):185-93.
6
Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.使用受体酪氨酸激酶EphA2衍生肽脉冲树突状细胞疫苗对小鼠结肠癌进行免疫治疗。
Cancer. 2007 Oct 1;110(7):1469-77. doi: 10.1002/cncr.22958.
7
Ephrin-As, Eph receptors and integrin α3 interact and colocalise at membrane protrusions of U251MG glioblastoma cells.Ephrin-As、Eph 受体和整合素 α3 在 U251MG 神经胶质瘤细胞的膜突起处相互作用和共定位。
Cell Biol Int. 2013 Oct;37(10):1080-8. doi: 10.1002/cbin.10134. Epub 2013 Jun 18.
8
Recruitment of Eph receptors into signaling clusters does not require ephrin contact.将Eph受体招募到信号簇中并不需要与 Ephrin 接触。
J Cell Biol. 2004 Mar 1;164(5):661-6. doi: 10.1083/jcb.200312001.
9
Putative dual role of ephrin-Eph receptor interactions in inflammation.Ephrin-Eph受体相互作用在炎症中的假定双重作用
IUBMB Life. 2006 Jul;58(7):389-94. doi: 10.1080/15216540600756004.
10
Structures of an Eph receptor tyrosine kinase and its potential activation mechanism.一种Eph受体酪氨酸激酶的结构及其潜在激活机制。
Acta Crystallogr D Biol Crystallogr. 2014 Dec 1;70(Pt 12):3135-43. doi: 10.1107/S1399004714021944. Epub 2014 Nov 22.
引用本文的文献
1
EphA2 regulates vascular permeability and prostate cancer metastasis via modulation of cell junction protein phosphorylation.EphA2通过调节细胞连接蛋白磷酸化来调控血管通透性和前列腺癌转移。
Oncogene. 2025 Feb;44(4):208-227. doi: 10.1038/s41388-024-03206-x. Epub 2024 Nov 7.
2
Oncological Ligand-Target Binding Systems and Developmental Approaches for Cancer Theranostics.肿瘤配体-靶向结合系统与癌症治疗诊断学的发展方法。
Mol Biotechnol. 2021 Mar;63(3):167-183. doi: 10.1007/s12033-020-00296-2. Epub 2021 Jan 9.
3
Silencing of COPB2 inhibits the proliferation of gastric cancer cells and induces apoptosis via suppression of the RTK signaling pathway.沉默 COPB2 通过抑制 RTK 信号通路抑制胃癌细胞的增殖并诱导细胞凋亡。
Int J Oncol. 2019 Apr;54(4):1195-1208. doi: 10.3892/ijo.2019.4717. Epub 2019 Feb 18.
4
Therapeutic potential of targeting the Eph/ephrin signaling complex.靶向 Eph/ephrin 信号复合物的治疗潜力。
Int J Biochem Cell Biol. 2018 Dec;105:123-133. doi: 10.1016/j.biocel.2018.10.006. Epub 2018 Oct 19.
5
Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers.Eph 受体和 Ephrin 配体在人类癌症中的差异表达模式。
Biomed Res Int. 2018 Feb 28;2018:7390104. doi: 10.1155/2018/7390104. eCollection 2018.
本文引用的文献
1
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors.使用针对Eph家族受体的治疗性单克隆抗体治疗血液系统恶性肿瘤的靶向疗法
Exp Hematol. 2017 Oct;54:31-39. doi: 10.1016/j.exphem.2017.07.003. Epub 2017 Jul 24.
2
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.EphA3 作为急性淋巴细胞白血病抗体免疫治疗的靶点。
Leukemia. 2017 Aug;31(8):1779-1787. doi: 10.1038/leu.2016.371. Epub 2016 Dec 6.
3
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.KB004，一种靶向受体酪氨酸激酶EphA3的首创单克隆抗体，用于晚期血液系统恶性肿瘤患者：1期研究结果。
Leuk Res. 2016 Nov;50:123-131. doi: 10.1016/j.leukres.2016.09.012. Epub 2016 Sep 28.
4
EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.EphA2是EphA2阳性白血病的治疗靶点，但对正常造血或白血病并非不可或缺。
PLoS One. 2015 Jun 17;10(6):e0130692. doi: 10.1371/journal.pone.0130692. eCollection 2015.
5
Therapeutic targeting of EPH receptors and their ligands.EPH 受体及其配体的治疗靶向。
Nat Rev Drug Discov. 2014 Jan;13(1):39-62. doi: 10.1038/nrd4175.
6
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.EphA3 维持肿瘤发生能力，是多形性胶质母细胞瘤的治疗靶点。
Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007.
7
Emerging strategies for EphA2 receptor targeting for cancer therapeutics.针对癌症治疗的 EphA2 受体靶向新兴策略。
Expert Opin Ther Targets. 2011 Jan;15(1):31-51. doi: 10.1517/14728222.2011.538682.
Zotero 插件